2. GPCR/G Protein Neuronal Signaling
  3. CGRP Receptor
  4. DD04107

DD04107 is a neuronal exocytosis inhibitor with a rat Syt1-C2B domain binding Ka of 2.4 μM. DD04107 interferes with synaptobrevin-syntaxin-SNAP-25 complex formation and Syt1-SNARE complex interaction to block α-calcitonin gene-related peptide (α-CGRP) exocytotic release from primary sensory neurons. DD04107 blocks inflammatory ion channel recruitment to nociceptor plasma membranes. DD04107 can be used for the research of chronic inflammatory pain, neuropathic pain, osteosarcoma pain, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, inflammatory pain.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

DD04107

DD04107 Chemical Structure

CAS No. : 1202877-06-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

DD04107 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DD04107 is a neuronal exocytosis inhibitor with a rat Syt1-C2B domain binding Ka of 2.4 μM. DD04107 interferes with synaptobrevin-syntaxin-SNAP-25 complex formation and Syt1-SNARE complex interaction to block α-calcitonin gene-related peptide (α-CGRP) exocytotic release from primary sensory neurons. DD04107 blocks inflammatory ion channel recruitment to nociceptor plasma membranes. DD04107 can be used for the research of chronic inflammatory pain, neuropathic pain, osteosarcoma pain, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, inflammatory pain[1][2].

In Vitro

DD04107 (5-50 μM; 1 h pretreatment) dose-dependently inhibits capsaicin-induced α-CGRP release from neonatal Wistar rat dorsal root ganglion primary sensory neurons in culture, with significant inhibition observed at 5 μM and stronger inhibition at 50 μM[1].
DD04107 (10 μM) does not exhibit significant binding affinity for most tested neuronal receptors, with only weak interactions (IC50 > 10 μM) observed for a small subset of receptors[1].
DD04107 (0.5-5 μM) does not inhibit hERG channel activity at 0.5 μM and 5 μM in human embryonic kidney 293 cells expressing hERG channels[1].
DD04107 (10 μM; 1 h) inhibits capsaicin-induced α-CGRP exocytosis from primary sensory nociceptor neurons isolated from neonatal Wistar rat dorsal root ganglia by 47%[2].
DD04107 binds selectively to the rat Syt1-C2B domain with a KD of 2.4 μM, and does not interact with the rat Syt7-C2B domain[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DD04107 Related Antibodies
Parmacokinetics
Species Dose Route Cmax AUC0-t Vss MRT0-t Tmax
Rat[1] 0.5 mg/kg i.v. 46.6 mg/L 78.3 mg·h/L 0.013 L 3.87 h 0 h
Rat[1] 5 mg/kg i.v. 461 mg/L 184 mg·h/L 0.020 L 2.71 h 0 h
Rat[1] 10 mg/kg s.c. 19.7 mg/L 283 mg·h/L 0.112 L 12.7 h 10.5 h
In Vivo

DD04107 (5 mg/kg; i.m.; single dose) displays potent in vivo anti-inflammatory and antihyperalgesic activity against carrageenan-induced inflammatory pain in Wistar rats[1].
DD04107 (1 mg/kg; i.m.; single dose) exhibits long-lasting (≥5 days) antihyperalgesic and antiallodynic activity against CFA-induced chronic inflammatory pain in Wistar rats[1].
DD04107 (0.1-0.5 mg/kg; s.c.; single dose) delivers long-lasting (up to 10 days) dose-dependent antihyperalgesic activity against vincristine-induced neuropathic pain in Sprague-Dawley rats[1].
DD04107 (0.5 mg/kg; s.c.; single dose) provides long-lasting (up to 12 days) antiallodynic activity against paclitaxel-induced neuropathic pain in Sprague-Dawley rats[1].
DD04107 (0.5-5 mg/kg; s.c.; single dose) exhibits dose-dependent antiallodynic activity lasting up to 24 hours against streptozotocin-induced diabetic neuropathic pain in CD1 mice[1].
DD04107 (0.1-3.0 mg/kg; s.c.; single dose) delivers potent, long-lasting (up to 7-8 days) dose-dependent antihyperalgesic and antiallodynic activity against osteosarcoma-induced bone cancer pain in C3H/He mice[1].
DD04107 (5 mg/kg; s.c.; single dose) produces antinociceptive activity in healthy Sprague-Dawley rats that is not mediated by opioid receptors[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar (male, ~150 g, intraplantar injection of 2% carrageenan solution)[1]
Dosage: 5 mg/kg
Administration: i.m.; single dose
Result: Attenuated paw volume increase to a degree identical to 10 mg/kg diclofenac.
Completely reversed carrageenan-induced mechanical hypersensitivity in the ipsilateral paw.
Did not affect the contralateral paw's nociceptive threshold.
Animal Model: Wistar (male, ~200 g, intraplantar injection of 1:1 oil/saline CFA emulsion)[1]
Dosage: 1 mg/kg
Administration: i.m.; single dose
Result: Produced a near-complete reversal of CFA-induced thermal hyperalgesia starting at ~4 hours post-administration.
Significantly increased mechanical nociceptive threshold and reduced withdrawal response frequency to mechanical stimuli.
Antiallodynic activity lasted at least 5 days post-administration.
Animal Model: Sprague-Dawley (male, ~300 g, intraperitoneal injection of vincristine sulfate three times per week for 2 weeks)[1]
Dosage: 0.1-0.5 mg/kg
Administration: s.c.; single dose
Result: Attenuated vincristine-induced mechanical hyperalgesia in a dose-dependent manner.
Significant antinociception observed at doses as low as 0.1 mg/kg.
Activity lasted up to 10 days post-administration.
Animal Model: Sprague-Dawley (male, ~250 g, intraperitoneal injection of paclitaxel on days 1, 3, 5, 7)[1]
Dosage: 0.5 mg/kg
Administration: s.c.; single dose
Result: Significantly attenuated paclitaxel-induced mechanical allodynia.
Antiallodynic effect lasted up to 12 days post-administration.
Animal Model: CD1 (male, 30-40 g, intraperitoneal injection of streptozotocin, blood glucose >250 mg/dl)[1]
Dosage: 0.5-5 mg/kg
Administration: s.c.; single dose
Result: Reduced streptozotocin-induced mechanical allodynia in a dose-dependent manner, with maximum effect at 4 hours post-administration.
5 mg/kg dose maintained significant activity up to 24 hours post-administration.
Residual non-significant activity detectable at 5 days.
Animal Model: C3H/He (male, 20-25 g, intratibial injection of 105 NCTC 2472 osteosarcoma cells)[1]
Dosage: 0.1-3.0 mg/kg
Administration: s.c.; single dose
Result: Attenuated osteosarcoma-induced thermal hyperalgesia in a dose-dependent manner, with complete reversal at 0.3 mg/kg and significant antinociception at 0.1 mg/kg lasting 2-4 days post-administration.
1 mg/kg dose fully reversed mechanical allodynia, with antiallodynic activity starting 24 hours post-administration and lasting up to 7-8 days.
Animal Model: Sprague-Dawley (male, ~300 g)[1]
Dosage: 5 mg/kg
Administration: s.c.; single dose
Result: Increased mechanical nociceptive threshold over 24 hours.
Antinociceptive effect was unaffected by pretreatment with the opioid receptor antagonist naltrexone.
Naltrexone completely abolished the effect of 3 mg/kg morphine.
Molecular Weight

1085.36

Formula

C48H88N14O12S
CAS No.
Sequence

palmitoyl-Glu-Glu-Met-Gln-Arg-Arg-NH2
Sequence Shortening

palmitoyl-EEMQRR-NH2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DD04107 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DD041071202877-06-2DD 04107DD-04107CGRP ReceptorCalcitonin gene-related peptide receptornociceptor plasma membranescalcitonin gene-related peptidehuman embryonic kidney 293 cellssynaptobrevin-syntaxin-SNAP-25 complexCa2+-dependent neuronal exocytosisα-calcitonin gene-related peptideSNARE complexprimary sensory neuronsrat Syt1-C2B domainSynaptotagmin-1 (Syt1)-C2B domainInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DD04107
Cat. No.:
HY-182539
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.